Hot Investor Mandate: Investment Arm of Europe HQ Corporate Invests Over $10M in Diagnostics and Monitoring Device Companies in USA, Europe and China

A corporate venture capital arm of a Europe-based corporate is focused on financial returns as well as bringing strategic value to the corporate. The firm makes equity investments in seed through growth rounds ranging from €1M-€5M for typical initial investments and may invest up to €10M-€12M over the life of the investment. The firm will lead, co-lead or follow and typically seeks a 10%-25% stake in the company. The firm is currently investing out of its third fund of €150M with a total of €450M AUM, and makes 10 investments per year. The firm focuses on North American, European, Chinese and Israeli companies.

The firm is only interested in diagnostics and monitoring devices with a particular interest in point-of-care diagnostics. Recent investments include an autonomous, mobile robot with delivery tracking software and a PCR-based diagnostic instrument for rapid pathogen detection, a connected blood glucose monitor and an enhanced PCR technology (laser PCR). The firm does not invest in traditional biopharma therapeutics and/or medical devices which require FDA approval.

The firm will work with all management teams, including first time entrepreneurs, and requires at least an observatory board seat with most investments requiring a standard board seat with voting rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.